New BioTrends Chart Audit Measures the Impact of Recent Multiple Sclerosis ... MarketWatch (press release) Patient profiles for the seven DMAs in late clinical development (teriflunomide, BG-12, alemtuzumab, PEG-Avonex, daclizumab, laquinimod, ocrelizumab) are also characterized. About BioTrends Research Group. BioTrends Research Group provides ... |
